Compare PARK & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PARK | PYPD |
|---|---|---|
| Founded | 1972 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.6M | 77.4M |
| IPO Year | N/A | 2014 |
| Metric | PARK | PYPD |
|---|---|---|
| Price | $17.17 | $4.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 26.9K | ★ 48.4K |
| Earning Date | 05-08-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.06 | N/A |
| Revenue Next Year | $6.17 | N/A |
| P/E Ratio | $6.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.29 | $2.30 |
| 52 Week High | $21.60 | $5.12 |
| Indicator | PARK | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 47.18 | 45.78 |
| Support Level | $14.41 | $4.01 |
| Resistance Level | $21.33 | $4.38 |
| Average True Range (ATR) | 1.26 | 0.18 |
| MACD | -0.29 | 0.01 |
| Stochastic Oscillator | 29.87 | 25.60 |
Park Dental Partners Inc is a dental resource organization (DRO) operating through its subsidiary. It Provides comprehensive business support services including clinical team members, administrative personnel, facilities and equipment to its affiliated general and multi-specialty dental practices throughout Minnesota and Wisconsin. Its network of affiliated dental practices provides both general and specialty dental services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics, under long-term agreements with initial terms of 30-years, with automatic 5-year renewals.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.